{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:36:58Z","timestamp":1780472218339,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.semarthrit.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T19:36:37Z","timestamp":1532028997000},"page":"406-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population"],"prefix":"10.1016","volume":"48","author":[{"given":"Alan J.","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Keystone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustratios","family":"Bananis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semarthrit.2018.07.006_bib0001","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.07.006_bib0002","first-page":"409","article-title":"Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.07.006_bib0004","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.07.006_bib0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-014-2857-y","article-title":"Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice","volume":"34","author":"Bykerk","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-016-1108-9","article-title":"Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials","volume":"18","author":"Teitsma","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hcl.2010.09.002","article-title":"Advances in the medical treatment of rheumatoid arthritis","volume":"27","author":"Kahlenberg","year":"2011","journal-title":"Hand Clin"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.07.006_bib0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.07.006_bib0009","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.07.006_bib0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.07.006_bib0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"9865","key":"10.1016\/j.semarthrit.2018.07.006_bib0013","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.07.006_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.07.006_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.semarthrit.2018.07.006_bib0016","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.07.006_bib0017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.07.006_bib0018","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.07.006_bib0019","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.07.006_bib0021","first-page":"683","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years","volume":"69 (Suppl 10)","author":"Wollenhaupt","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"10093","key":"10.1016\/j.semarthrit.2018.07.006_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.07.006_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.semarthrit.2018.07.006_bib0024","first-page":"437","article-title":"Fiducial limits for the Poisson distribution","volume":"28 (3-4)","author":"F.","year":"1936","journal-title":"Biometrica"},{"issue":"10","key":"10.1016\/j.semarthrit.2018.07.006_bib0025","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.07.006_bib0026","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2018.07.006_bib0027","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rhematol"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.07.006_bib0028","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying anti-rheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken.)"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2018.07.006_bib0029","article-title":"Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy [abstract]","volume":"67","author":"Winthrop","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.07.006_bib0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.07.006_bib0031","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.07.006_bib0033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217308156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217308156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T18:13:41Z","timestamp":1560363221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217308156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0049017217308156"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}